Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4

Andrea Volonté, Tiziano Di Tomaso, Michela Spinelli, Matilde Todaro, Francesca Sanvito, Luca Albarello, Massimiliano Bissolati, Luca Ghirardelli, Elena Orsenigo, Soldano Ferrone, Claudio Doglioni, Giorgio Stassi, Paolo Dellabona, Carlo Staudacher, Giorgio Parmiani, Cristina Maccalli

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display "tumor-initiating/stemness" properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients. The Journal of Immunology, 2014, 192: 523-532.

Original languageEnglish
Pages (from-to)523-532
Number of pages10
JournalJournal of Immunology
Volume192
Issue number1
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Immunologic Monitoring
Interleukin-4
Colorectal Neoplasms
T-Lymphocytes
Membranes
Neoplasms
In Vitro Techniques
Immunotherapy
Neoplastic Stem Cells

ASJC Scopus subject areas

  • Immunology

Cite this

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. / Volonté, Andrea; Di Tomaso, Tiziano; Spinelli, Michela; Todaro, Matilde; Sanvito, Francesca; Albarello, Luca; Bissolati, Massimiliano; Ghirardelli, Luca; Orsenigo, Elena; Ferrone, Soldano; Doglioni, Claudio; Stassi, Giorgio; Dellabona, Paolo; Staudacher, Carlo; Parmiani, Giorgio; Maccalli, Cristina.

In: Journal of Immunology, Vol. 192, No. 1, 01.01.2014, p. 523-532.

Research output: Contribution to journalArticle

Volonté, A, Di Tomaso, T, Spinelli, M, Todaro, M, Sanvito, F, Albarello, L, Bissolati, M, Ghirardelli, L, Orsenigo, E, Ferrone, S, Doglioni, C, Stassi, G, Dellabona, P, Staudacher, C, Parmiani, G & Maccalli, C 2014, 'Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4', Journal of Immunology, vol. 192, no. 1, pp. 523-532. https://doi.org/10.4049/jimmunol.1301342
Volonté, Andrea ; Di Tomaso, Tiziano ; Spinelli, Michela ; Todaro, Matilde ; Sanvito, Francesca ; Albarello, Luca ; Bissolati, Massimiliano ; Ghirardelli, Luca ; Orsenigo, Elena ; Ferrone, Soldano ; Doglioni, Claudio ; Stassi, Giorgio ; Dellabona, Paolo ; Staudacher, Carlo ; Parmiani, Giorgio ; Maccalli, Cristina. / Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. In: Journal of Immunology. 2014 ; Vol. 192, No. 1. pp. 523-532.
@article{51d5fa5c150845efb0462b839d47deb6,
title = "Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4",
abstract = "Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display {"}tumor-initiating/stemness{"} properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients. The Journal of Immunology, 2014, 192: 523-532.",
author = "Andrea Volont{\'e} and {Di Tomaso}, Tiziano and Michela Spinelli and Matilde Todaro and Francesca Sanvito and Luca Albarello and Massimiliano Bissolati and Luca Ghirardelli and Elena Orsenigo and Soldano Ferrone and Claudio Doglioni and Giorgio Stassi and Paolo Dellabona and Carlo Staudacher and Giorgio Parmiani and Cristina Maccalli",
year = "2014",
month = "1",
day = "1",
doi = "10.4049/jimmunol.1301342",
language = "English",
volume = "192",
pages = "523--532",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4

AU - Volonté, Andrea

AU - Di Tomaso, Tiziano

AU - Spinelli, Michela

AU - Todaro, Matilde

AU - Sanvito, Francesca

AU - Albarello, Luca

AU - Bissolati, Massimiliano

AU - Ghirardelli, Luca

AU - Orsenigo, Elena

AU - Ferrone, Soldano

AU - Doglioni, Claudio

AU - Stassi, Giorgio

AU - Dellabona, Paolo

AU - Staudacher, Carlo

AU - Parmiani, Giorgio

AU - Maccalli, Cristina

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display "tumor-initiating/stemness" properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients. The Journal of Immunology, 2014, 192: 523-532.

AB - Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display "tumor-initiating/stemness" properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients. The Journal of Immunology, 2014, 192: 523-532.

UR - http://www.scopus.com/inward/record.url?scp=84891121499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891121499&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1301342

DO - 10.4049/jimmunol.1301342

M3 - Article

VL - 192

SP - 523

EP - 532

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -